Science First: Understanding the Potential Mechanisms of Action of Investigational Anti-Depressants

Add this event to your calendar:
14/11/2016 18:00 14/11/2016 21:00 America/Los_Angeles Science First: Understanding the Potential Mechanisms of Action of Investigational Anti-Depressants The Ultimate Skybox , Diamond View Tower, East Village , San Diego , CA 92101 JLABS San Diego together with Janssen R&D false DD/MM/YYYY
November
14
Event

Science First: Understanding the Potential Mechanisms of Action of Investigational Anti-Depressants

The Ultimate Skybox , Diamond View Tower, East Village , San Diego , CA 92101

November 14, 2016 from 18:00 PM to 21:00 PM (PST)

$10 - $35


Mood disorders are among the most common medical disorder with lifetime prevalence rates ranging from 14% to 16% for major depressive disorder (MDD). The WHO ranks MDD as the highest global cause of "years of life lost due to illness or disability" on a population basis, and projects that in 2030 MDD also will rank first in global disease burden, as measured in Disability Adjusted Life Years (DALYs). Mood disorders also are associated with elevated mortality rates, especially due to suicide and cardiovascular disease.

There is a tremendous need for effective and rapidly-acting antidepressant treatments. Traditional antidepressants, which target monoamine systems, have limited efficacy and may take weeks if not months to deliver therapeutic benefit.

Johnson & Johnson Innovation, JLABS (JLABS) is bringing in experts from across neuroscience to discuss the emerging science behind fast-acting antidepressants, and the challenges and opportunities in the field. Hear from folks who are leading the scientific efforts and those who bring a broad perspective on the future of depression treatment.


Agenda:
5:00 PM | Registration Opens, Networking Reception
6:00 PM | Panel Presentations
7:00 PM | Audience Participation/Q&A
7:30 PM | Networking
8:00 PM | Program Close


Speakers - partial list:
Ronald Duman | Professor of Psychiatry and Neurobiology; Director, Abraham Ribicoff Research Facilities; Jameson Professor, Yale University School of Medicine read bio»
John Isaac | Sr. Director, Scientific Project Lead, Neuroscience, Janssen R&D read bio»
Husseini Manji | Global TA Head Neuroscience, Janssen R&D read bio»
Lisa Monteggia | Professor, Department of Neuroscience; Ginny and John Eulich Professorship holder, UT Southwestern Medical Center read bio»


Co-hosts:
Co-hosted by Declan Jones, VP, Neuroscience Scientific Innovation at Johnson & Johnson Innovation, London and Guy Seabrook, VP, Neuroscience Innovation at Johnson & Johnson Innovation, California.


About the Science First series:
The purpose of the Science First series, sponsored by Johnson & Johnson Innovation, JLABS, is to bring together top experts to explore a pressing topic in their scientific field. This is the fourth such event organized during Society for Neuroscience and it is a chance for conference attendees, local scientists, and entrepreneurs to present and dialogue on new discoveries, advancing techniques, and other cutting-edge science themes.


Fees:
Free | SfN Conference Attendees, Academic & Entrepreneurs


Location:
The Ultimate Skybox
Diamond View Tower, East Village
350 10th Avenue
San Diego, CA


Speakers' Biographies:

Ronald Duman, Ph.D. | Professor of Psychiatry and Neurobiology; Director, Abraham Ribicoff Research Facilities; Elizabeth Mears and House Jamison Professor of Psychiatry, Yale University School of Medicine
Dr. Duman is Professor of Psychiatry and Neurobiology, Director of the Abraham Ribicoff Research Facilities, and the Jameson Professor of Psychiatry at Yale. Studies from Dr. Duman's laboratory have contributed to characterization of the molecular and cellular actions of stress, depression, and antidepressant treatments, providing the basis for a neurotrophic and synaptic hypothesis of depression. These findings represent major advances in our understanding of the effects of antidepressants and provide a framework for the development of novel therapeutic agents. Dr. Duman has received several awards for his work, including the Anna-Monika Prize, Nola Maddox Falcone Prize, Janssen Prize, NIMH MERIT Award, and a NARSAD Distinguished Investigator Award. He is author of over 300 original articles, reviews and chapters and has given over 250 invited lectures.



John Isaac | Sr. Director, Scientific Project Lead, Neuroscience, Janssen R&D
John joined Johnson & Johnson in September 2016. In this role John uses his drug discovery and scientific experience to identify and advance external opportunities in the areas of Alzheimer’s Disease and Mood Disorders. Prior to joining Johnson & Johnson, since November 2014, John was Head of Neuroscience and Mental Health at the Wellcome Trust. Previous to that he worked at Eli Lilly and Company at their neuroscience research campus near London, UK. At Lilly he led a team of labs dedicated to identifying new therapies for Alzheimer’s disease and schizophrenia. John’s scientific interests centre on synaptic mechanisms in circuit function, and how dysfunction causes psychiatric and neurological disease. John obtained a BSc in Pharmacology and Biochemistry at the University of Southampton in 1990 and remained at Southampton for his graduate work, studying mechanisms of epilepsy with Prof Howard Wheal. In 1994 he joined Dr Robert Malenka’s laboratory at University of California San Francisco working on mechanisms of long-term synaptic plasticity in hippocampus and somatosensory cortex, also in close collaboration with Dr Roger Nicoll. After completion of this post doc position, John joined Prof Graham Collingridge’s laboratory at the University of Bristol back in the UK in 1996, where he completed a one year post doc before establishing his own lab there. He rose up through the ranks to full Professor before leaving in 2004 to set up a lab at the Intramural Program at NINDS/NIH in Bethesda, MD, USA studying mechanisms and roles of synaptic plasticity in developing cortical circuits.



Husseini Manji, M.D., F.R.C.P.C. | Global Therapeutic Head for Neuroscience, Janssen Research & Development, LLC
Husseini K. Manji, M.D., F.R.C.P.C. is the Global Therapeutic Head for Neuroscience at Janssen Research & Development, LLC, one of the Johnson & Johnson pharmaceutical companies. He was previously Chief, Laboratory of Molecular Pathophysiology & Experimental Therapeutics, NIH, and director of the NIH Mood and Anxiety Disorders Program, the largest program of its kind in the world. He is also a visiting professor at Duke University. Dr. Manji received his B.S. (Biochemistry) and M.D. from the University of British Columbia. The major focus of his research has been the investigation of disease- and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity in neuropsychiatric disorders. Dr. Manji is a previous recipient of numerous research and clinical awards, including the NIMH Director's Career Award for Significant Scientific Achievement, the A. E. Bennett Award for Neuropsychiatric Research, the Ziskind-Somerfeld Award for Neuropsychiatric Research, the NARSAD Mood Disorders Prize, the Mogens Schou Distinguished Research Award, the American College of Neuropsychopharmacology (ACNP)'s Joel Elkes award for distinguished research, the Canadian Association of Professors Award, the Brown University School of Medicine Distinguished Researcher Award, the DBSA Klerman Senior Distinguished Researcher Award, the American Federation for Aging Research Award of Distinction, the Global Health & The Arts Award of Recognition, the Inaugural University of Michigan Greden Scholar in Residence Award, the Briggs Pharmacology Lectureship Award and the NIMH award for excellence in clinical care and research.



Lisa Monteggia, Ph. D. | Professor, Department of Neuroscience; Ginny and John Eulich Professorship holder, UT Southwestern Medical Center
Dr. Lisa Monteggia is a Professor in the Department of Neuroscience and holds the Ginny & John Eulich Professorship at UT Southwestern Medical Center. Her lab focuses on the role of the molecular and cellular basis of neural plasticity as it pertains to neuropsychiatric disorders. She is working to elucidate the mechanisms underlying antidepressant efficacy. She is also studying the role of MeCP2, the gene linked to Rett syndrome, on synaptic plasticity and behavior. Her research encompasses molecular, cellular, behavioral and electrophysiological approaches using mouse models. Dr. Monteggia received a B.S. and M.S. from the University of Illinois at Urbana-Champaign. She then worked in a pharmaceutical company where she concurrently attended Chicago Medical School receiving a Ph.D. in Neuroscience. She then moved to Yale University to work in the area of Molecular Psychiatry. She later joined the Department of Psychiatry at UT Southwestern as an Assistant Professor. Dr. Monteggia has received numerous awards including the Daniel X. Freedman Award for outstanding research from the National Alliance for Research on Schizophrenia and Depression (NARSAD), the Rising Star Award from the International Mental Health Research Organization (IMHRO), and the Daniel H. Efron Award for outstanding basic/translational research by the American College of Neuropsychopharmacology (ACNP). Dr. Monteggia is an Associate Editor of Neuropsychopharmacology and a member of the editorial boards of the Journal of Neuroscience, Journal of Biological Chemistry and Biological Psychiatry. She has served on grant review panels for the National Institutes of Health as well as numerous scientific foundations.



JLABS San Diego together with Janssen R&D

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), with New York City, opening in June 2018, and Shanghai in 2019. For more information please visit www.jlabs.jnjinnovation.com or follow @JLABS.

Event contact


Related content